These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22028089)

  • 1. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
    Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
    Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
    Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma.
    Okubo S; Kojima M; Matsuda Y; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Mino-Kenudson M; Takahashi S
    Sci Rep; 2019 Nov; 9(1):17145. PubMed ID: 31748528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
    Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
    Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time to stop checking frozen section neck margins during pancreaticoduodenectomy?
    Lad NL; Squires MH; Maithel SK; Fisher SB; Mehta VV; Cardona K; Russell MC; Staley CA; Adsay NV; Kooby DA
    Ann Surg Oncol; 2013 Oct; 20(11):3626-33. PubMed ID: 23838908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
    Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.
    Jamieson NB; Foulis AK; Oien KA; Going JJ; Glen P; Dickson EJ; Imrie CW; McKay CJ; Carter R
    Ann Surg; 2010 Jun; 251(6):1003-10. PubMed ID: 20485150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
    Taherian M; Wang H
    Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
    Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
    Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
    Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
    Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy.
    Carpenter EL; Van Decar SG; McCarthy PM; Valdera FA; Adams AM; O'Shea AE; Smolinsky T; Thomas K; Clifton GT; Newhook TE; Peoples GE; Nelson DW; Vreeland TJ
    J Surg Oncol; 2024 Jul; 130(1):109-116. PubMed ID: 38801055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
    Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
    World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
    World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.